MannKind ends Afrezza promotion agreement with Sanofi

[anonymous]

VALENCIA, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) (MNKD) today announced the termination of its license and collaboration agreement with sanofi-aventis U.S. LLC for the development and commercialization of Afrezza® (insulin human) Inhalation Powder. The parties will promptly commence transition discussions in order to effect a smooth and orderly transition in the development and commercialization of Afrezza from Sanofi to MannKind over the next 90 – 180 days. In any event, termination of the license agreement in its entirety will be effective no later than six months from the effective date of Sanofi’s notice of termination, or July 4, 2016.

MannKinda to hold CONFERENCE CALL today.

MannKind will host a conference call at 4:30 pm (Eastern Time) on January 5, 2016. To participate in the live call by telephone, please dial (888) 771-4371 or (847) 585-4405 and use the participant passcode: 4155 4306. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at http://www.mannkindcorp.com.

 

[anonymous]

An epic launch failure with guilt on Sanofi management for stumbling through this. What a mess.

 

[anonymous]

It was a joke from the being. Management did not know what to do or say, changed tactics let changing their pants. Always blaming the reps that they could not sell.

 

[anonymous]

And Sanofi impacts other companies employees as well.....sad

 

[anonymous]

Sanofi changes selling message at least 5 times. Not to mention the lung function teat which they were clueless about. Also finger- pointing field sales in typical Sanofi fashion only showed what a gutless bunch Afrezza marketing and sales management was. Scott O needs to be thrown out on the sidewalk by this Friday and anybody that was on launch team should be clearing out their desks tomorrow morning. Lots of pissed off investors with lawsuits coming.

 

[anonymous]

Sanofi changes selling message at least 5 times. Not to mention the lung function teat which they were clueless about. Also finger- pointing field sales in typical Sanofi fashion only showed what a gutless bunch Afrezza marketing and sales management was. Scott O needs to be thrown out on the sidewalk by this Friday and anybody that was on launch team should be clearing out their desks tomorrow morning. Lots of pissed off investors with lawsuits coming.

 

[anonymous]

Brandicourt, Witz and the French govt should curtail alcohol consumption

You peeps are looking really STUPIDE

ca va? ca va biean? Tu es ignorante? Idiotes?

.....mon dieu

 

[anonymous]

Sanofi changes selling message at least 5 times. Not to mention the lung function teat which they were clueless about. Also finger- pointing field sales in typical Sanofi fashion only showed what a gutless bunch Afrezza marketing and sales management was. Scott O needs to be thrown out on the sidewalk by this Friday and anybody that was on launch team should be clearing out their desks tomorrow morning. Lots of pissed off investors with lawsuits coming.

*sigh* Lessee here….we've crapped our pants with launches for several meds including Xyzal, AuviQ, and Afrezza. How long can we live off of that freak occurrence of Lantus launch and market domination? That world (2007-2011) is long gone, what with all of the new market entries and newfound strength of PBMs and payers on Rx.

We really and truly should be a case study at St Joes Pharma marketing MBA (a joke in itself), and at real B schools